Abstract
Albumin is currently employed as a plasma expander to prevent and treat specific complications of cirrhosis with ascites, such as the prevention of paracentesis-induced circulatory dysfunction and renal dysfunction induced by spontaneous bacterial peritonitis, as well as the diagnosis and treatment of acute kidney injury and hepatorenal syndrome. Recently, evidence has shown that long-term albumin administration in patients with decompensated cirrhosis reduces mortality and incidence of complications, eases the management of ascites, is cost effective, and has a good safety profile.
Author supplied keywords
Cite
CITATION STYLE
Tufoni, M., Zaccherini, G., Caraceni, P., & Bernardi, M. (2020, June 1). Albumin: Indications in chronic liver disease. United European Gastroenterology Journal. SAGE Publications Ltd. https://doi.org/10.1177/2050640620910339
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.